Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tivorsan Pharmaceuticals Inc.

http://www.tivorsan.com/

Latest From Tivorsan Pharmaceuticals Inc.

Biotech Investment Outlook Remains Strong Despite Jitters

Despite the recent volatility in the stock market, experts and industry insiders at the BIO CEO & Investor conference in New York said biotech remains a leading area to invest, predicting continued VC investment and more M&A ahead.

Financing M & A

Keeping Track: Janssen Gets A Breakthrough Therapy Status, FDA Awards Two Orphan Drug Designations, Portola Lands A CRL

The latest drug development news and highlights from our FDA Performance Tracker.

Drug Review Review Pathway

Execs On The Move, October 2015

Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

BioPharmaceutical Medical Device

Protein Arrays: When Genes Are Not Enough

There's growing conviction that gene arrays are less useful than first imagined for expression studies and diagnostics--and that directly reading protein expression will more likely provide an accurate picture of biological status-health, disease, and pharmaceutical response. Thus, a number of companies have started up to create, on the analogy of gene arrays, protein arrays, to allow the simultaneous and quantitative testing of large numbers of proteins-potentially thousands.But the task is easier said than done. First, there are too few proteins known to allow testing for worthwhile expression patterns; and, second, because of the delicacy and variety of proteins, surface chemistry and other problems have historically made arrays impractical. None of this daunts the start-ups who, opportunistic, are looking to exploit the markets they think they can get to first: clinical diagnostics and pharmaceutical clinical development programs.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register